Us Bancorp \De\ Pro Qr Therapeutics N.V. Transaction History

Us Bancorp \De\

$75.6 Billion
Q4 2024

A detailed history of Us Bancorp \De\ transactions in Pro Qr Therapeutics N.V. stock. As of the latest transaction made, Us Bancorp \De\ holds 2,214 shares of PRQR stock, worth $3,630. This represents 0.0% of its overall portfolio holdings.

Number of Shares

2,214

Holding current value

$3,630

% of portfolio

0.0%

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 05, 2025	BUY	$1.81 - $4.49 $4,007 - $9,940	2,214 New	2,214 $6,000
Q2 2022 Aug 01, 2022	SELL	$0.56 - $1.0 $2,848 - $5,087	-5,087 Closed	0 $0
Q1 2022 May 11, 2022	SELL	$0.9 - $8.39 $307 - $2,869	-342 Reduced 6.3%	5,087 $5,000
Q4 2021 Feb 11, 2022	BUY	$6.58 - $8.44 $11,422 - $14,651	1,736 Added 47.01%	5,429 $43,000
Q3 2021 Nov 10, 2021	BUY	$5.16 - $8.47 $10,474 - $17,194	2,030 Added 122.07%	3,693 $31,000
Q2 2021 Aug 05, 2021	BUY	$5.75 - $7.59 $9,562 - $12,622	1,663 New	1,663 $11,000
Q2 2020 Aug 07, 2020	SELL	$4.5 - $6.53 $3,681 - $5,341	-818 Closed	0 $0
Q1 2020 May 13, 2020	BUY	$5.25 - $9.9 $3,003 - $5,662	572 Added 232.52%	818 $5,000
Q4 2019 Feb 04, 2020	BUY	$5.84 - $10.51 $1,436 - $2,585	246 New	246 $2,000

Others Institutions Holding PRQR

# of Institutions

Shares Held

45.1M

Call Options Held

31.4K

Put Options Held

24.7K

Adage Capital Partners Gp, L.L.C. Boston, MA

9.6M
Shares

$15.7 Million
0.05% of portfolio
Privium Fund Management B.V.

4.99M
Shares

$8.18 Million
3.12% of portfolio
Woodline Partners LP San Francisco, CA

3.56M
Shares

$5.83 Million
0.07% of portfolio
Israel Englander Millennium Management LLC | New York, Ny

2.83M
Shares

$4.64 Million
0.0% of portfolio
Affinity Asset Advisors, LLC New York, NY

2.83M
Shares

$4.63 Million
1.38% of portfolio

View Full List

About ProQR Therapeutics N.V.

Ticker PRQR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 71,362,096
Market Cap $117M
Description
ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III clinical trial illuminate trial for treating leber congenital amaurosis 10 disease; and ultevursen, which is in phase II/III clin...

More about PRQR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Us Bancorp \De\, based on Form 13F filings with the SEC.

News

Stay updated on Us Bancorp \De\ with notifications on news.

Account